证券代码：002688 证券简称：金河生物 公告编号：2025-107 关于出售资产的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 2025 年 10 月 29 日，金河生物科技股份有限公司（以下简称"公司"、"乙 方"）召开了第六届董事会第三十三次会议审议通过《关于出售资产的议案》。 公司拟向内蒙古托克托经开区招投建设发展有限责任公司（以下简称"招投公司"、 "甲方"）出售拥有所有权的金河六期蒸汽长输管道，金额为人民币 21,121,234 元（含税）。具体内容如下： 一、交易概述 1、公司拥有所有权的金河六期蒸汽长输管道（以下简称"标的资产"）总 长为 5,257.78 米，是公司六期工程生产过程中使用蒸汽自建的蒸汽长输管道。 金河六期蒸汽长输管道位于由呼铝热电厂围墙内低压分汽缸接出，至金河公司院 内的蒸汽长输管道，向南跨人行道，经运铝专线路东沿绿化带向南，在大唐铁路 北护坡处向西，在铁路北护坡桥下穿过 S103，继续沿铁路北护坡向西后拐入金 河大街，沿金河大街路南绿化带向西，沿复兴路西绿化带向北，在中石环保东墙 沿复兴路西绿化带向西， ...

Group 1 - The core point of the article is that Jinhe Biological announced the convening of its 33rd board meeting on October 29, 2025, to review the third-quarter report for 2025 [1] - For the first half of 2025, Jinhe Biological's revenue composition is as follows: veterinary chemical drugs accounted for 61.83%, agricultural product processing accounted for 19.76%, veterinary biological products accounted for 11.12%, environmental protection business accounted for 4.97%, and others accounted for 2.15% [1] - As of the report date, Jinhe Biological has a market capitalization of 5.2 billion yuan [1] Group 2 - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with technology leading the market's transformation into a new "slow bull" pattern [1]

Group 1 - Company Jinhe Biology reported Q3 performance with revenue of approximately 2.036 billion yuan, an increase of 22.86% year-on-year [1] - The net profit attributable to shareholders was about 139 million yuan, reflecting a year-on-year increase of 22.25% [1] - Basic earnings per share reached 0.1803 yuan, up 23.41% compared to the previous year [1] Group 2 - As of the report, Jinhe Biology's market capitalization stands at 5.2 billion yuan [2]

证券代码：002688 证券简称：金河生物 公告编号:2025-108 金河生物科技股份有限公司 关于接受控股股东无偿借款暨关联交易的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 二、关联方的基本情况 1、基本情况 | 公司名称 | 内蒙古金河控股有限公司 | | --- | --- | | 注册地址 | 内蒙古自治区呼和浩特市托克托县新坪路81号 | | 统一社会信用代 码 | 91150122MA0QQPB945 | | 类型 | 有限责任公司（自然人投资或控股） | | 注册资本 | 2,118万元 | | 法定代表人 | 王东晓 | | 成立日期 | 2020年6月30日 | | 经营范围 | 以自有资金从事投资活动；企业管理。 | | 主要股东和实际 | 公司董事长王东晓持有金河控股82%的股权，路牡丹女士持有金河控股18% | | 控制人 | 的股权。 | 2、历史沿革、主要业务最近三年发展状况 金河生物科技股份有限公司（以下简称"公司"或"金河生物"）于2025 年10月29日召开第六届董事会第三十三次会议，审议通过了《关于接 ...

金河生物科技股份有限公司 第六届监事会第二十七次会议决议公告 本公司及监事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）第六届监事会第二十七次 会议于 2025 年 10 月 19 日以电子邮件方式发出通知，并于 2025 年 10 月 29 日以 通讯方式召开。会议由监事会主席张千岁先生主持，应到监事 3 人，实到监事 3 人，本次监事会出席会议监事人数符合法律法规，会议合法有效。会议召开符合 《中华人民共和国公司法》等法律、法规和《公司章程》的规定。与会监事以通 讯表决的方式审议通过了以下议案： 证券代码：002688 证券简称：金河生物 公告编号：2025-105 三、备查文件 1、监事会决议 一、以 3 票同意，0 票反对，0 票弃权审议通过了《关于金河生物科技股份 有限公司 2025 年第三季度报告的议案》。 经审核，监事会认为董事会编制和审核公司 2025 年第三季度报告的程序符 合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公 司的实际情况，不存在任何虚假记载、误导性陈述或者重大 ...

Revenue and Profit - The company's revenue for Q3 2025 was CNY 645,942,171.20, representing a 9.20% increase year-over-year, while year-to-date revenue reached CNY 2,036,199,952.22, up 22.86% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2025 was CNY 1,149,590.21, a significant decrease of 94.94% year-over-year, with year-to-date net profit at CNY 139,068,189.51, an increase of 22.25%[5] - The basic and diluted earnings per share for Q3 2025 were both CNY 0.0015, down 94.90% from the same quarter last year[5] - The net profit for Q3 2025 was CNY 134,780,194.66, an increase of 19.3% compared to CNY 113,065,440.05 in the same period last year[37] - The total profit for the period was CNY 160,750,511.35, an increase of 29.3% from CNY 124,210,778.64 in the same quarter last year[37] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 5,584,971,110.18, a decrease of 1.16% from the end of the previous year[5] - Total liabilities decreased to ¥2,985,226,288.81 from ¥3,150,724,813.22, a decline of 5.2%[34] - The total equity attributable to shareholders increased by 4.58% year-over-year, reaching CNY 2,349,509,857.26[5] - The total equity attributable to shareholders rose to ¥2,349,509,857.26 from ¥2,246,607,845.93, an increase of 4.6%[35] Cash Flow - The company’s cash flow from operating activities for the year-to-date was CNY 364,247,585.56, reflecting a decrease of 4.04%[5] - Cash flow from financing activities decreased by 780,066,049.21 yuan, a decline of 42.28%, primarily due to reduced borrowing and repayment of more maturing debts[23] - Net cash increase in cash and cash equivalents decreased by 296,085,837.75 yuan, a decline of 130.21%, mainly due to reduced financing activities[24] - The net cash flow from operating activities was CNY 364,247,585.56, slightly down from CNY 379,581,732.41 in the previous year[39] - The cash and cash equivalents at the end of the period were CNY 519,657,637.46, a decrease from CNY 725,025,045.03 year-over-year[39] Expenses and Impairments - Research and development expenses increased by 51.10% year-over-year, amounting to CNY 28,951,969.12, as the company enhanced its competitiveness through increased investment[15] - The company reported a significant decrease in net profit after deducting non-recurring gains and losses, which fell by 118.45% year-over-year to CNY -3,246,231.76 for Q3 2025[5] - Income tax expenses increased by 14,824,978.10 yuan, an increase of 133.02%, driven by improved overall performance and profit growth, particularly from subsidiary PharmaWay[17] - Cash paid for various taxes increased by 43,029,542.50 yuan, a rise of 99.93%, reflecting the company's sustained operational performance[19] - Credit impairment losses decreased by 2,086,965.35 yuan, a reduction of 58.41%, mainly due to intensified collection efforts resulting in recovery of long-overdue receivables[16] - Asset impairment losses decreased by 16,236,415.71 yuan, a decline of 93.64%, attributed to reduced provisions for inventory write-downs as prices rebounded and unit costs decreased[16] Stock and Shareholder Information - Total number of common shareholders at the end of the reporting period was 50,527[26] - The company approved the release of 4,826,000 restricted stocks, accounting for 0.63% of the total share capital of 771,634,398 shares[28] - The first release date for the restricted stocks under the 2023 incentive plan is set for July 21, 2025[29] - The company has approved 570,000 stock options for 22 eligible participants, representing 0.74% of the total share capital, with an exercise price of 2.84 yuan per share[30] Other Financial Metrics - Fair value gains increased by 134,289.65 yuan, a growth of 172.91% compared to the same period last year, primarily due to stock price recovery of other listed companies held by subsidiary Hangzhou Youben[16] - The company reported a net investment loss of ¥1,139,097.30 compared to a loss of ¥631,039.01 in the previous period[36] - The total operating revenue for the period reached ¥2,036,199,952.22, an increase of 22.9% compared to ¥1,657,273,697.64 in the previous period[36] - Total operating costs amounted to ¥1,893,954,187.39, up 23.7% from ¥1,530,578,504.10 in the prior period[36] - The company did not undergo an audit for the Q3 financial report[40]

具体内容详见公司同日于巨潮资讯网（http://www.cninfo.com.cn）及《证 券时报》、《中国证券报》、《证券日报》和《上海证券报》披露的《关于出售 资产的公告》。 三、以 5 票同意，0 票反对，0 票弃权审议通过了《关于接受控股股东无偿 借款暨关联交易的议案》。 证券代码：002688 证券简称：金河生物 公告编号：2025-104 金河生物科技股份有限公司 第六届董事会第三十三次会议决议公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）第六届董事会第三十三次 会议于 2025 年 10 月 19 日以电子邮件方式发出通知，并于 2025 年 10 月 29 日以 通讯方式召开，会议由董事长王东晓先生主持，应到董事 9 人，实到董事 9 人， 本次董事会出席会议董事人数符合法律法规，会议合法有效。会议召开符合《中 华人民共和国公司法》等法律、法规和《公司章程》的规定。与会董事以通讯表 决的方式审议通过了以下议案： 一、以 9 票同意，0 票反对，0 票弃权审议通过了《关于金河生物科技 ...

Group 1 - The core point of the article is that Jinhe Biological has announced the pledge of shares by its controlling shareholder, Jinhe Holdings, which does not pose any risk to the company's operations or governance [1] - As of the announcement date, Jinhe Holdings has pledged a total of 85.32 million shares, accounting for 38.92% of its holdings, while the total pledged shares by Jinhe Holdings and its concerted parties account for 33.3% of their holdings [1] - Jinhe Biological's revenue composition for the first half of 2025 is as follows: veterinary chemical drugs 61.83%, agricultural product processing 19.76%, veterinary biological products 11.12%, environmental protection business 4.97%, and others 2.15% [1] Group 2 - The current market capitalization of Jinhe Biological is 5.2 billion yuan [1] - The article also highlights the broader context of the biopharmaceutical market in China, noting that this year, overseas licensing has generated $80 billion [1]

Core Viewpoint - Jinhe Biological announced that its controlling shareholder, Jinhe Holdings, will release the pledge of 21.87 million shares on October 23, 2025, which accounts for 9.98% of its holdings and 2.83% of the company's total share capital [1] Summary by Relevant Sections - **Share Pledge Release** - Jinhe Holdings will解除质押2187万股, representing 9.98% of its holdings and 2.83% of the total share capital of Jinhe Biological [1] - **Current Pledge Status** - As of the announcement date, Jinhe Holdings has cumulatively pledged 85.32 million shares, which is 38.92% of its holdings and 11.06% of the total share capital of the company [1]

Core Viewpoint - The animal health sector experienced a slight increase of 0.21% on October 24, with significant contributions from specific stocks, particularly Biological Shares, which led the gains [1] Market Performance - The Shanghai Composite Index closed at 3950.31, up 0.71% - The Shenzhen Component Index closed at 13289.18, up 2.02% [1] Stock Performance in Animal Health Sector - Biological Shares (600201) closed at 10.77, up 2.87% with a trading volume of 311,900 shares and a turnover of 333 million yuan - Other notable stocks include: - *ST Green Health (002868): closed at 29.09, up 0.66% - Shunlian Biological (688098): closed at 10.75, up 0.66% - Huisheng Biological (300871): closed at 20.75, up 0.48% - Yongshun Biological (920729): closed at 9.68, up 0.31% - Jinhe Biological (002688): closed at 6.68, unchanged [1] Capital Flow Analysis - The animal health sector saw a net inflow of 8.6031 million yuan from institutional investors, while retail investors experienced a net outflow of 24.4195 million yuan [2] - The breakdown of capital flow indicates: - Repu Biological (300119) had a net inflow of 9.2707 million yuan from institutional investors - Biological Shares (600201) saw a net inflow of 8.4244 million yuan - Kexin Biological (688526) had a net inflow of 5.4428 million yuan from institutional investors [3]